| Name | ivacaftor |
|---|---|
| Synonyms |
2,4-DI-TERT-BUTYL-5-HYDROXYPHENYL)-4-OXO-1,4-DIHYDROQUINOLINE-3-CBOXAMID
Ivacaftor D6 Ivacaftor VX-770(Ivacattor) N-[2,4-Bis(tert-butyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxo-3-quinolinecboxamide N-(2,4-Di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-cboxaMide Ivacato KALYDECO;IVACAFTOR;VX770;VX N-(2,4-ditert-butyl-5-hydroxyphenyl)-4-oxo-1H-quinoline-3-carboxamide MFCD17171361 Evacaftor N-[5-Hydroxy-2,4-bis(2-methyl-2-propanyl)phenyl]-4-oxo-1,4-dihydro-3-quinolinecarboxamide Ivacaftor, 10 mM in DMSO Ivacaftor-D4 Ivacaftor API N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide Ivacaftor in methanol IVACAFTOR (VX-770);VX VX 770, Ivacaftor CFTR Potentiator VX-770 Ivacaftor [14C]-Ivacaftor N-[2,4-Bis(tert-butyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxo-3-quinolinecboxamide Ivacaftor (VX-770) CFTR Potentiator, VX-770 3-QuinolinecboxaMide, N-[2,4-bis(1,1-diMethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxo Kalydeco VX770 VX-770 VX-770 vacaftor Ivacaftor Impurity UNII-1Y740ILL1Z VX-770, Ivacaftor, Kalydeco N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxaraide N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquino VX-770 ISO 9001:2015 REACH N-(2,4-DITERT-BUTYL-5-HYDROXYPHENYL)-4-OXO-1H-QUINOLINE-3-CBOXAMIDE IvacaftorQ: What is Ivacaftor Q: What is the CAS Number of Ivacaftor Q: What is the storage condition of Ivacaftor Q: What e the applications of Ivacaftor Ivacaftor, >= N-[2,4-Bis(tert-butyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxo-3-quinolinecarboxamide |
| Description | Ivacaftor is a potent and orally bioavailable CFTR potentiator, targeting G551D-CFTR and F508del-CFTR with EC50s of 100 nM and 25 nM, respectively. |
|---|---|
| Related Catalog | |
| Target |
EC50: 100 nM (G551D-CFTR), 25 nM (F508del-CFTR)[1] |
| In Vitro | Ivacaftor (10 µM) increases the PC secretion activity by 3-fold for ABCB4-G535D, 13.7-fold for ABCB4-G536R, 6.7-fold for ABCB4-S1076C, 9.4-fold for ABCB4-S1176L, and 5.7-fold for ABCB4-G1178S. Ivacaftor corrects the functional defect of ABCB4 mutants[1]. Ivacaftor (10 μM) significantly increases CFTR activity in W1282X-expressing cells compared to R1162X CFTR cells[2]. Ivacaftor shows no significant activity against 160 targets tested including the GABAA benzodiazepine receptor. Ivacaftor increases the chloride secretion with an EC50 of 0.236 ± 0.200 μM, a 10-fold shift in potency compared to the F508del HBEs[3]. In recombinant cells, VX-770 increases CFTR channel open probability (Po) in both the F508del processing mutation and the G551D gating mutation. VX-770 increases forskolin-stimulated IT in temperature-corrected F508del-FRT cells by appr 6-fold with an EC50 of 25 nM[4]. |
| In Vivo | Ivacaftor (1-200 mg/kg, p.o.) exhibits good oral bioavailability in rat[3]. |
| References |
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Boiling Point | 550.5±50.0 °C at 760 mmHg |
| Molecular Formula | C24H28N2O3 |
| Molecular Weight | 392.491 |
| Flash Point | 286.7±30.1 °C |
| Exact Mass | 392.209991 |
| PSA | 85.68000 |
| LogP | 6.34 |
| Vapour Pressure | 0.0±1.5 mmHg at 25°C |
| Index of Refraction | 1.606 |
| Storage condition | 2~8℃ |
| HS Code | 29333990 |
|---|
| Precursor 9 | |
|---|---|
| DownStream 2 | |